Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024
April 26, 2024 07:05 ET
|
Y-mAbs Therapeutics, Inc.
NEW YORK, April 26, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended...
Y-mAbs to Present at 2024 ASCO Annual Meeting
April 25, 2024 16:05 ET
|
Y-mAbs Therapeutics, Inc.
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer
March 14, 2024 09:05 ET
|
Y-mAbs Therapeutics, Inc.
NEW YORK, March 14, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors
March 04, 2024 07:30 ET
|
Y-mAbs Therapeutics, Inc.
NEW YORK, March 04, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
February 29, 2024 16:05 ET
|
Y-mAbs Therapeutics, Inc.
Record DANYELZA® net product revenues of $23.4 million and $84.3 million for Q4 and FY 2023 represents YoY growth of 42% and 71%, respectively Cash and cash equivalents of $78.6 million as of December...
Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024
February 16, 2024 07:30 ET
|
Y-mAbs Therapeutics, Inc.
NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter and full...
Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024 16:05 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index
December 13, 2023 16:05 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
November 13, 2023 16:05 ET
|
Y-mAbs Therapeutics, Inc
Q3 2023 DANYELZA® net product revenues of $20.0 million represents YoY growth of 59%U.S. FDA clearance of IND for CD38-SADA for relapsed or refractory non-Hodgkin LymphomaCash and cash equivalents of...
Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023
October 31, 2023 07:05 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the third quarter ended...